3 Recession-Proof Dividend Stocks You Can't Go Wrong With in July

The article argues recession risk is easing but not disappearing—J.P. Morgan estimated a 35% global recession probability for 2026—while shifting focus to “recession-proof” dividend stocks. Kroger Q1 revenue rose to $46.1B (from $45.1B) and EPS increased to $1.58 (from $1.49), helped by 19% YoY e-commerce growth and a 2.5% dividend yield. UnitedHealth reports Q1 revenue of $111.7B (+2% YoY), raised FY outlook to >$17.35/share (from $17.10), and cites a federal-approved 2.48% average Medicare Advantage rate increase for 2027; WM posted Q1 revenue of $6.22B (+3.5% YoY) and EPS of $1.79 (+$0.21 YoY) with a 1.6% dividend yield.

Analysis

This is less a stock-picker’s revelation than a factor setup: if recession odds rise, the market usually rewards cash conversion, pricing power, and balance-sheet durability before it rewards true earnings growth. That argues for relative winners, not blanket defensives. On that lens, WMT is the cleaner grocery trade than KR because scale and supplier leverage let it defend share without leaning as hard on margin sacrifice; KR can benefit from trade-down, but the upside is capped once the market fully prices the recession scenario.

KR’s private-label mix is helpful only if consumers trade down faster than input costs and wage pressure reaccelerate. If the downturn is mild, that mix tailwind can stall because the consumer still trades up selectively to larger chains and club formats, which is why WMT and COST are the higher-quality beneficiaries in a stress case. UNH is a different animal: the earnings support is mainly about medical-cost normalization and the 2027 rate backdrop, so recession is not the key driver; the real risk is that utilization stays elevated and the market overestimates how quickly government rate relief flows through.

WM is the strongest compounder here, but the market often treats waste as fully non-cyclical when industrial volume and recycling spreads can still soften for multiple quarters in a real slowdown. The defensive bid is likely to compress dispersion rather than create a broad upside rerating, so chasing these names after a macro scare is usually poor risk/reward. Contrarian view: the consensus may be understating how quickly WMT can take share from KR in a downturn, while overestimating how much UNH benefits from one favorable reimbursement decision alone.

Key Decisions for Investors

• Prefer long WMT vs. KR over the next 1-3 months if recession data deteriorates; WMT has better scale, pricing power, and share-gain optionality, while KR’s benefit is more vulnerable to promo pressure and mix drag.
• Use WM as the highest-quality defensive long in the group on pullbacks, but size modestly; risk/reward improves only if macro weakens without a simultaneous collapse in industrial volumes. Falsifier: sustained volume deterioration in WM’s commercial routes or recycling spreads.
• Avoid chasing UNH on the back of reimbursement headlines alone; wait for the next quarter to confirm medical-cost trend normalization. Falsifier: another quarter of elevated utilization or a pause in guidance improvement.
• If you want a recession-hedge basket, pair long WM + WMT against a consumer-discretionary short basket rather than buying KR outright; that captures trade-down and pricing power without relying on the weakest moat in the group.
• Treat KR as a tactical watch item, not a core long, until you see evidence that private-label mix is translating into gross-margin expansion rather than just traffic. If management signals heavier promo spend, back away.